Abstract: To investigate alterations in lipoprotein composition associated with carbon tetrachloride-induced rat liver injury, electrophoretic patterns of rat apoproteins were investigated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and compared with those in man. Rat apoprotein (apo) A-I and apo E were shown to migrate the same distances as those of man, though rat apo A-II + apo C-II and apo C-III migrated farther. Administration of 1.0 mi/kg CCl4 decreased the lipid contents, the very low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein (HDL) fractions in the serum. Transaminase activity and total protein (TP) content increased with increased CCl4 administration. The percentage of albumin nonesterified fatty acid (Alb-NEFA) increased and HDL2 fraction decreased. Administration of 1.0 ml/kg CCl4 decreased apo C-I and apo E in the HDL fraction. The bands of apo A-I, apo A-II, apo A-II + apo C-II and apo E in the HDL fraction declined after 2.0 ml/kg CCl4 administration. Apoproteins in the VLDL + LDL fraction appeared to decrease after CCl4 treatment. It was suggested that lipoprotein abnormalities induced by CCl4 application may be related to inhibition of apoprotein synthesis, suppression of lipoprotein lipase activity, and the decline of HDL2.
Introduction
Recent pharmacological studies of lipid metabolism have focused on determination of lipoprotein composition and apoprotein levels. Among many reports of lipoproteins, investigation of high density lipoprotein (HDL) seems to be of great interest, since HDL is a protective lipoprotein against premature development of atherosclerotic diseases.1,2) Although lipoprotein fractions, such as very low density lipoprotein (VLDL), low density lipoprotein (LDL), and HDL are separated by ultracentrif ugation or chemical procedures, apoprotein analysis is performed mainly by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) or isoelectric focusing (IEF). 3, 4) Both the composition and function of apoproteins obtained from normal human serum have been studied.
It is also well known that various disease-induced hyperlipemia and liver diseases frequently develop abnormalities in lipid levels and lipoprotein compositions in human plasma or serum. 7, 8) It is generally accepted that the composition and functions of human serum can be extrapolated from data obtained in experimental animals, yet few studies of lipoprotein and apoprotein patterns of Department of Pharmacology, Sliowa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142, Japan, INAGAKI, et content of the HDL fraction (Tables I and 2 ). After CCl4 administered at 1.0 ml/kg, PL contents decreased significantly in serum and VLDL+LDL fraction. In contrast, administration of 2.0 ml/kg CCl4 produced TC and PL contents in the serum comparable to control levels. The TG content of VLDL+LDL and HDL fractions was decreased by administration of 0.2 ml/kg CCl4. This decline became greater after administration of 1.0 ml/kg CCl4. Administration at 2.0 ml/kg CCl4 tended to increase the TG contents of every fraction, but not significantly. All three doses of CCl4, increased serum TP levels. The protein content of VLDL+LDL fraction was significantly decreased by 1.0 ml/kg CCl4 while at 2.0 ml/kg CCl4 did not cause significant change. Administrations of CCl4 markedly decreased the pro- tein content of HDL fraction (Tables 1 and 2 ). Changes in lipoprotein population: Densitometrical analysis of polyacrylamide gel disk electrophoresis revealed rat serum lipoprotein migration bands cf VLDL (pre beta-lipoprotein), LDL (beta-lipoprotein), HDL1, HDL2, HDL3 (alpha-lipoproteins) and Alb-NEFA (Fig. 2) . Percentages of VLDL and LDL fractions were not changed by administrations of 0.2 and 1.0 ml/kg CCl4. Administration of CCI,I at 2.0 ml/kg slightly increased VLDL and LDL percentages, but not significantly. The percentage of Alb-NEFA increased significantly after CCl4 treatment at all three doses. Administration of CCl4 decreased HDL3 percentage. Administration of 2.0 ml/kg CCL significantly increased in HDL, percentage and markedly decreased HDL2 and HDL:3 (Fig. 2) .
Changes in apoprotein contents of HDL fraction: Changes in HDL apoproteins are shown in Fig. 3 . The stained bands of cytochrome c mixture , a molecular weight marker for SDS-PAGE, were in order from the bottom: figures in parenthesis are molecular weight: monomer (12300), dimer (24600), trimer (36900), tetramer (49200) , pentamer (61500), and hexamer (73800) (Fig. 3) .
Changes in HDL apoproteins were measured with densitometry of the electrophoretic bands and expressed as percentages of control values in Fig. 4 . Apo C-I and apo E significantly decreased with administration of 1.0 mI/kg CCl4. Significant declines of apo A-I , apo A-II, apo A-1l+apo C-II, and apo E were induced by 2.0 ml/kg CCl4. The apo C-I level, at 2.0 ml/kg, was similar to the control level, although the value at 2.0 ml/kg had a large standard deviation. Changes in VLDL+LDL apoproteins: Electrophoretic patterns of VLDL+LDL apoproteins separated by SDS-PAGE are shown in Fig. 5 . A control electrophoretic pattern showed clearly stained bands of apo A-I, apo C-I, apo A-II+C-II, apo C-111 and apo E. Administrations of 0.2 and 1.0 ml/kg CCI weakened the apo A-I, apo A-II+C-II and apo E of bands. Administration of 2.0 ml/kg CCl4 induced an increase in apo C-I, and decreases in apo A-I, apo A-II+C-I1, and apo E.
Apo B, which is not water soluble and has a high molecular weight, does not migrate in the gel employed in this study. Therefore, densitometrical analysis of apo B could not be performed. When VLDL+LDL apoprotein contents were expressed in comparison with the control value, all apoproteins except apo C-I tended to decrease after CCl4 treatments at all three doses. Administration of 2.0 ml/kg CCl4 produced an apo C-I level comparable to the control level.
Discussion
Our results demonstrated that rat apoprotein patterns in HDL fraction produced in SDS-PAGE were similar to those of humans since the migration distances were almost the same.
The respective molecular weights of human and rat apoproteins are as follows: apo A -I (28300, 27000), apo A-II (8690, 8000), apo C-I (6631 , 7000)) apo C-II (8837, 8000), apo C-III (8764, 10000), apo E (34000, 35000) .20) The anhydrous molecular weights of apo C-I and apo C-III are 6631 and 8837 , respectively.21,22) The migration ranges of human apo A-II+apo C-II and apo C-III differed from those of rats . The difference between the molecular weights of these proteins of rats and of man might account for the differenc e in migration distances since a heavier molecule moves less . Although rat apo A-II had been thought to exist as a monomer, the band of rat apo A-II in the present study migrated the same distance as the human apo A-II, which is identified as a dimer (molecular weight 17414).20) Thus, from our data we could not deny the possibility that rat apo A -II may be present in a dimeric form. The present study proved that SDS-PAGE and isoelectric focusing, the methods generally employed for human apoprotein determination , could be adapted for the determination of rat apoproteins . Accumulation of detailed data on apoproteins in animals, i.e., their normal levels and changes due to CCl4-induced liver damage , should be indispensable for developing a disease model of human hepatic disorder .
CCl4-induced liver injury is a useful experimental model .23) Subcutaneous injection of 1.0 ml/kg CCl4 is supposed to trigger centrizonal steatosis and necrosis in the liver .24) It decreases serum lipid and TP levels, and increases serum transaminases . In the present study, CCI, treatment induced liver damage dose-dependently , and increased remarkably serum transaminase activity. The lipid and protein contents of lipoprotein fractions were decreased from the control level at the lower two doses of 0 .2 ml/kg and 1.0 ml/kg, and were comparable to the control level at the highest dose, 2 .0 ml/kg. This might reflect the process of necrosis in the liver.
CCl4 increased Alb-NEFA and decreased HDL2 observed in electrophoretic analysis of serum lipoproteins. The increase in Alb-NEFA may reflect an increase in the amount of release of TG decomposition products from the liver , where TG accumulated. The decrease in HDL2 percentage indicates inhibition of the conversion of HDL3 to HDL 2. Especially, the decrease in apo E content of the HDL fraction by CC! 1 administrations at 0 .2 ml/kg and 1.0 ml/kg correlated with the decrease in conversion from HDL3 to HDL 2. Felker et al. reported that apo E was a major protein component of both VLDL and HDL in rat liver perfusates.25) The apo E content of HDL3 may control the conversion. Furthermore, the decline of the HDL3 percentage induced by 2 .0 ml/kg CC!1 suggests inhibition of HDL3 synthesis. The decreases of apo A-I, apo A-II, apo A-II+apo C-II , and apo E contents of the HDL fraction by 2.0 ml/kg CCl4 correlated with the decreases of protein and lipid contents of the HDL fraction. These decreases also indicate suppression of apoprotein synthesis in the liver. In the VLDL+LDL fraction, the administration of CCI , at 2.0 ml/kg increased lipids and apoproteins which had been decreased by 1 .0 ml/kg of CCI,. This might reflect VLDL+LDL metabolism alterations , such as reduction of lipoprotein lipase activity in serum due to the decrease of apo C-II.
Galactosamine induces diffusing hepatocellular injury which closely resembles human hepatitis. Galactosamine is widely used to produce an experimental liver damage model ,26) but its injury form and resulting changes in serum lipid levels differ from those induced by CC!,. Sirowej et al.10) reported that apo A-II and apo C's in VLDL and HDL diminished with galactosamine treatment. Cartwright et al. 27 ) also reported that galactosamine-induced hepatitis in rats was associated with various alterations in plasma; increased contents of unesteri-fled cholesterol, PL, and TG, severe deficiency of lecithin-cholesterol acyl transferase (LCAT), and the appearance of discoidal lipoproteins. In addition, decline of apo C-III in the VLDL fraction, and increase of apo E as well as decrease of apo C's in the HDL fraction were triggered by galactosamine treatment. Investigators who employed lower doses of galactosamine detected no changes in apo A-I or apo E content of the HDL fraction after galactosamine treatment.
In the present study, we demonstrated that apoprotein changes in CCl4-induced liver injury differed from those in galactosamine-induced liver injury. Administration of 1.0 ml/kg CCI, decreased the apo E content of the HDL fraction, which was opposite to the effect of galactosamine treatment. HDL, an apo E-rich HDL fraction, proved to be a better LCAT substrate than any other HDL fraction in serum. Lipoprotein abnormalities in the galactosamine-induced LCAT deficiency, familial LCAT deficiency , and patients with liver disease, emphasize the central role of LCAT in plasma lipoprotein metabolism.10) CCl4 treatment suppressed protein synthesis, decreased protein content in HDL fractions and reduced HDL2
percentages. Especially, the decline of HDL percentage upon administration of 2.0 ml/kg CCl4 might be caused by the inhibition of LCAT activity and the decrease of Apo A-I level. In summary, our data suggest that lipoprotein abnormalities induced by CCL may be related to inhibition of apoprotein synthesis, suppression of lipoprotein lipase activity , and the decline of HDL2 percentage. Also, our data revealed differences between changes due to CCl4-and galactosamine-induced liver injuries in rat. The understanding of such detailed differences in experimental animals will be important in developing an appropriate disease model of human hepatic disorder.
